Real-world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed-dose combination to prevent chemotherapy-induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy.

Autor: Md Yusof M; Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia., Abdullah MM; Subang Jaya Medical Centre, Subang Jaya, Selangor, Malaysia., Yap BK; Subang Jaya Medical Centre, Subang Jaya, Selangor, Malaysia., Ng SC; Subang Jaya Medical Centre, Subang Jaya, Selangor, Malaysia., Low JSH; Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia., Lam KS; Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia., Ahmad Badruddin RBA; Dr A. Radzi's Integrated Oncology Clinic and Daycare Centre, Johor Bahru, Malaysia., Lai CNB; Sunway Medical Centre, Petaling Jaya, Selangor, Malaysia., Lau KL; Borneo Medical Centre, Kuching, Sarawak, Malaysia., Chong KJ; Mahkota Medical Centre, Melaka, Malaysia., Nonis JG; Pantai Hospital Ayer Keroh, Melaka, Malaysia., Ahmad Annuar MA; Prince Court Medical Centre, Kuala Lumpur, Malaysia., Abdul Rahman MHFB; Subang Jaya Medical Centre, Subang Jaya, Selangor, Malaysia.

Publikováno v: Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2022 Aug; Vol. 18 (4), pp. 419-427. Date of Electronic Publication: 2021 Nov 23.